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INTRODUCTION: Adiponectin is a circulating hormone that is produced exclusively by adipocytes and has anti-
inflammatory and anti-atherogenic properties. The hypothesis that there are differences in adiponectin levels
between stable and unstable coronary-artery disease patients remains controversial. Furthermore, the potential
relationships between the plasma adiponectin level and the inflammatory and non-inflammatory markers (oxidized
low density lipoprotein and nitric oxide) in patients with stable and unstable coronary-artery disease relative to
normal subjects have not been assessed.
OBJECTIVES: To assess whether plasma adiponectin levels differ among patients with stable and unstable coronary-
artery disease and among control subjects, and to correlate plasma adiponectin level with inflammatory and clinical
risk factors (such as oxidized-LDL and nitric oxide) in these patients.
METHODS: This study included 50 control subjects, 50 stable angina patients and 50 unstable angina patients with
angiographically documented coronary-artery disease. Plasma adiponectin and oxidized-LDL levels were
determined using an enzyme immunoassay. Plasma nitric oxide, high sensitivity C-reactive protein and lipid profile
levels were also measured.
RESULTS: Plasma adiponectin levels were lower in the unstable angina patients (4.9¡1.30 mg/mL) than in the stable
angina patients (6.34¡1.0 mg/mL) or in the controls (9.25¡1.8 mg/mL); these levels were also significantly lower in
stable angina patients versus controls (p,0.001). Plasma adiponectin levels were negatively correlated with
oxidized-LDL, high sensitivity C-reactive protein, lipid profile and other clinical risk factors but positively correlated
with nitric oxide.
CONCLUSION: Plasma adiponectin levels were found to be lower in both stable and unstable angina patients
relative to control subjects, and the correlation between plasma adiponectin and cardiovascular markers is
weakened in these patients.
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INTRODUCTION
Adiponectin is a circulating hormone that is produced
exclusively by adipocytes
1 and has both anti-inflammatory
and anti-atherogenic properties.
2
Endothelial dysfunction due to reduced nitric oxide (NO)
bioavailability is an essential early event in the development,
propagation, and clinical expression of atherosclerosis and its
complications.
3
Oxidized-LDL (Ox-LDL) has a prominent role in the
pathogenesis of atherosclerosis,
4 and the elevation of ox-
LDL levels in atherosclerotic plaques is an important event
in the development of atherosclerosis.
5 Moreover, elevated
ox-LDL contributes to plaque instability and vulnerability.
6
Adiponectin may protect the endothelium against the
detrimental effects of ox-LDL.
7 Low adiponectin levels are
associated with high circulating ox-LDL in patients with
type 2 diabetes mellitus and coronary artery disease.
8
Adiponectin hampers proatherogenic events, such as
nuclear factor kB signaling, foam cell formation, and
vascular smooth cell migration.
9,10 It also promotes NO
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1129production by endothelial cells
11 and suppresses the
proliferation of human aortic smooth muscle cells.
12
Decreased levels of adiponectin act as an independent
risk factor for coronary artery disease.
13 In patients with
stable chest pain, low adiponectin levels may contribute to
coronary plaque vulnerability and may play a role in the
pathophysiology of acute coronary syndrome.
14 Also, low
plasma adiponectin in patients with stable coronary artery
disease is associated with the presence of thin-cap
fibroatheroma, which is a criterion for plaque vulnerabil-
ity.
15 Previous studies have demonstrated that low adipo-
nectin levels are an independent predictor of the extent of
coronary artery disease and coronary lesion complexity, as
determined by coronary angiography.
16-18
Despite the aforementioned relationships between adipo-
nectin levels and coronary artery disease, the existence of
differences in adiponectin levels between stable and
unstable coronary artery disease patients is controversial.
In one study of 608 patients with stable angina and 378
patients with unstable angina, conducted by Stefan et al,
19
no significant differences in adiponectin levels were
observed between the two groups of patients. In contrast,
another study found that the plasma levels of adiponectin
were significantly lower in patients with unstable angina
pectoris relative both to patients with stable angina pectoris
and to the control group.
20 In addition, in other acute
settings (such as acute coronary syndrome and myocardial
infarction), plasma adiponectin levels are lower relative to
stable coronary artery disease patients.
17,21
The relationships between plasma adiponectin levels and
the inflammatory and non-inflammatory markers ox-LDL
and NO in patients with stable and unstable coronary artery
disease relative to normal subjects have not yet been
assessed. Furthermore, the differences in adiponectin levels
between stable and unstable coronary artery disease
patients require further evaluation.
Therefore, in the present study, we sought to assess
whether plasma adiponectin levels differ among patients
with stable angina, unstable angina, and control subjects,
and whether these differences correlate with inflammatory
and clinical risk factors, such as ox-LDL and NO.
MATERIALS AND METHODS
Patients
Between 22 November 2009 and 22 May 2010, 150 patients
receiving coronary angiograghy following chest pain,
clinical manifestations or suspected changes on electrocar-
diography were selected for inclusion in this study at
Isfahan Cardiovascular Research Center in Iran. These
subjects included 50 stable angina patients, 50 unstable
angina patients, and 50 control subjects. The patient’s
angiograms were assessed by two experienced cardiologists
who were unaware of the disease status of each subject. The
position and extent of stenosis for 15 main coronary
segments were determined according to the method of
Miller et al.
22 Coronary artery disease was defined as $50%
stenosis in at least one main coronary segment. In the
majority of the normal subjects, coronary artery obstructions
were less than 10%, but a minority of them (15 subjects)
presented stenosis of less than 25% in at least one main
coronary artery segment. In addition, the control subjects
did not have any history or clinical symptoms of cardio-
vascular disease. Among the patients with significant
stenosis, 80 patients (85%) had 50 to 75% stenosis in at least
one main coronary artery segment, and 20 patients (20%)
had 76 to 85% stenosis in one main coronary artery segment.
Furthermore, 85 patients (85%) had single vessel stenosis,
10 patients (10%) had double vessel stenosis and 5 patients
(5%) had triple vessel stenosis. All of the patients were
evaluated both prospectively at enrollment and retrospec-
tively by review of their clinical history. The unstable angina
patients had random and unpredictable angina at rest or
sleep along with transient ST-segment shifts and normal
creatine kinase MB levels, whereas the stable angina
patients had chest pain during physical exertion that was
relieved by rest and presented a constant pattern or
frequency of chest pain. Patients with myocardial infarction
diagnosed on the basis of ST-segment elevation on their
electrocardiogram and high levels of creatine kinase MB,
lactate dehydrogenase and troponin T were not included in
the study.
Information about conventional clinical risk factors, such
as smoking, diabetes mellitus, family history of coronary
artery disease, hypertension, medication and other neces-
sary data, were obtained through a standardized question-
naire after admission.
Patients with a recent (within 6 months) myocardial
infarction, cardiovascular event, surgery (within 3 months),
cancer, infection or inflammatory disease were not included
in the study. Any patient that underwent any other
diagnostic or therapeutic treatment or who experienced a
cardiovascular event that might have interfered with the
study within one week after the angiography was excluded.
Before enrollment, written informed consent was obtained
from all of the subjects and approval of the study was
provided by the Ethics Committee of Isfahan University
Medical Sciences and Isfahan Cardiovascular Research
Center (ICRC, a WHO collaborating center).
Biochemical measurements
One week after the angiography, a 12-hour fasting venous
blood sample was collected from each patient into a
Vacutainer EDTA-tube (BD VacutainerH, Brocken Bow, NE
USA), centrifuged and stored at -70˚C until analyses were
performed. Plasma adiponectin levels were determined
with an enzyme-linked immunosorbent (ELISA) assay kit
(Cat. EA-0201, Signosis, Inc.). Ox-LDL was measured with
an ELISA kit (Immundiagnostik AG, Bensheim, Germany).
Total nitric oxide (NO) was determined by spectrophoto-
metry using a total NO assay kit (Assay designs, Inc., USA).
Plasma levels of hsCRP were measured with a highly
sensitive latex-enhanced immunoturbidometric assay
(Randox laboratory Ltd, Belfast, United Kingdom). Plasma
total lipoprotein profiles (total cholesterol, triglycerides,
LDL-cholesterol, and HDL-cholesterol) were determined
using enzymatic test kits (Pars Azmun Co., Karaj, Iran).
Statistical analysis
All of the statistical analyses were performed using SPSS
statistical software version 16.0 (SPSS Inc., Chicago, IL,
USA). The sample size was determined by a power analysis
based on preliminary results that were obtained in our
research center. With a type I error of ,0.05 (2-tailed),
power (1-b) of 0.80, an expected difference in adiponectin
concentration between patients and normal subjects of
about 1.4 mg/mL and a standard deviation of about
2.5 mg/mL, a minimum of 49 subjects in each group would
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concentration.Beforethestatisticalanalysis,thevariableswere
examined for normal distribution and approved by the
Shapiro-Wilk test. The comparison of means for continuous
variables among the groups was performed using the
unpaired Student’s t-test or one-way analysis of variance
(ANOVA) with post hoc comparison using the Bonferoni test,
and the Chi-square test was applied to the dichotomous
variables. Correlations between the plasma concentration of
adiponectin and other normally distributed variables were
assessed by Pearson’s coefficient of correlation (r). Multiple
logistic regression analysis was performed to determine the
relationship between adiponectin levels and the presence of
stable angina or unstable angina. The data are expressed either
as mean ¡standard deviationor as counts and percentages. A
p-value ,0.05 was considered to be statistically significant.
RESULTS
The clinical characteristics and biochemical data of the
patientsare summarized in Table 1.Thecontrolsubjects were
age- and gender-matched with the patients. Cardiovascular
risk factors were observed predominantly in the patients.The
control subjects were mostly not taking medications. The
inflammatory markers hsCRP and ox-LDL were significantly
higher in the angina patients relative to the control subjects,
and they were higher in the unstable angina patients relative
to the stable angina patients. The lipid profiles varied among
the three groups, although these differences failed to reach
significance, with the exception of LDL-cholesterol, which
was significantly higher in the unstable angina patients than
in the control subjects (p=0.009).
As shown in Figure 1, the plasma adiponectin levels were
significantly lower in the unstable angina patients
(4.90¡1.3 mg/mL) than in the stable angina patients
(6.34¡1.0 mg/mL) or in the control subjects (9.25¡1.8
mg/mL), and they were lower in the stable angina patients
than in the control subjects (p,0.001; Table 1).
There was a significant inverse relationship between
adiponectin and ox-LDL levels in the unstable angina patients
(r=-0.447, p=0.001), stable angina patients (r=-0.379,
p=0.007), and control subjects (r=-0.406, p=0.003) (Figure 2).
In all of the patients, plasma adiponectin levels correlated
positively with plasma total NO levels. The correlations were
stronger in the control subjects (r=0.534, p=0.01) than in the
unstable angina patients (r=0.448, p=0.01) or in the stable
angina patients (r=0.405, p=0.01). Furthermore, total NO
Table 1 - Clinical characteristic of the study participants.
Variable Controls (n=50)
Stable angina
patients (n=50)
Unstable angina
patients (n=50)
Controls vs.
stable angina
patients
(p-value)
Controls vs. unstable
angina patients
(p-value)
Stable angina vs.
unstable angina
patients (p-value)
Age (year) 58.9¡10.3 61.2¡11.23 59.9¡10.45 0.510 0.576 0.587
Men 35 (70%) 28 (56%) 32 (64%) 0.350 0.473 0.396
BMI (kg/m
2) 26.9¡0.6 27.8¡1.5 26.89¡1.3 0.387 0.483 0.376
Total Cholesterol
(mg/dL)
178.3¡47.0 192.9¡36.3 199.5¡55.8 0.123 0.073 0.214
Triglycerides (mg/dL) 147.4¡36.3 159.3¡80.5 161.9¡95.6 0.112 0.073 0.231
LDL-cholesterol
(mg/dL)
96.8¡27.5 109.4¡23.8 113.5¡31.5 0.072 0.009 0.106
HDL-cholesterol
(ng/dL)
46.1¡9.5 44.7¡9.6 41.8¡11 0.108 0.099 0.444
hsCRP (mg/L) 1.9¡1.3 3.2¡1.4 4.0¡1.7 ,0.001 ,0.001 0.031
Ox-LDL (ng/mL) 54.0¡19.0 85.9¡10.17 110.0¡20 ,0.001 ,0.001 ,0.001
Total NO (mmol/L) 103.0¡21.0 74.3¡22.0 54.5¡19.0 ,0.001 ,0.001 ,0.001
Adiponectin (mg/mL) 9.25¡1.8 6.34¡1.0 4.9¡1.30 ,0.001 ,0.001 ,0.001
Hypertension 3(6) 20(40) 20(40) ,0.001 ,0.001 1.000
Diabetes mellitus 1(2) 12(24) 20(40) ,0.001 ,0.001 ,0.001
Family history of CAD 10(20) 20(40) 30(60) ,0.001 ,0.001 0.001
Smoking 2(4) 8(16) 15(30) ,0.001 ,0.001 ,0.001
Statins 2(4) 18(36) 28(56) ,0.001 ,0.001 ,0.001
Aspirin 0(0) 28(56) 32(64) ,0.001 ,0.001 0.156
Antiplatelets 0(0) 20(40) 20(40) ,0.001 ,0.001 1.000
Nitrates 0(0) 15(30) 15(30) ,0.001 ,0.001 1.000
Data are expressed as mean ¡ SD or number (%); BMI, body mass index; LDL-cholesterol, low density lipoprotein-cholesterol; HDL-cholesterol, high
density lipoprotein-cholesterol; hsCRP, high sensitivity C-Reactive Protein; NO, nitric oxide; CAD, coronary artery disease.
Figure 1 - Plasma adiponectin levels in unstable angina patients,
stable angina patients and control subjects (ANOVA, p,0.001 for
all and between groups). n, number of subjects in each group.
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1131levels were significantly higher in the control subjects than in
the angina patients, and they were higher in the stable angina
patients than in the unstable angina patients (Figure 3).
The angina patients exhibited a trend toward higher
levels of cholesterol, triglycerides, LDL-cholesterol, hsCRP
and a lower level of HDL-cholesterol compared with the
control subjects, but with the exception of hsCRP levels,
these differences were not statistically significant (Table 1).
We also assessed the association between plasma adipo-
nectin levels and conventional cardiovascular risk factors
among the subjects. These correlations are presented in
Table 2. As shown, no significant correlation was found
between age, total cholesterol or HDL-cholesterol and
adiponectin level.
We did not find a significant difference in plasma
adiponectin levels between patients with and without drug
therapy. The stable and unstable angina patients did not
differ with respect to the extent of coronary artery stenosis
or the number of affected arteries. Among all of the subjects,
plasma adiponectin levels were higher in women than in
men (7.0¡2.0 mg/mL vs. 6.7¡2.4 mg/mL, p=0.034).
To look for an independent association of plasma
adiponectin level with the presence of stable versus unstable
angina, a multiple logistic regression analysis was per-
formed adjusting for age, gender and other clinical risk
factors. As shown in Table 3, a low plasma adiponectin level
was an independent predictor for both stable and unstable
angina (OR=0.51, p=0.023; OR=0.59, p=0.001, respec-
tively). Other predictors for the presence of stable and
unstable angina, respectively, were age (OR=1.26, p=0.022;
OR=1.43, p=0.042), hsCRP (OR=1.62, p=0.033; OR=1.37,
p=0.003), ox-LDL (OR=1.78, p=0.014; OR=2.01, p=0.038),
total NO (OR=0.61, p=0.008; OR=0.76, p=0.012, negative
predictor), statins (OR=0.64, p=0.050, negative predictor
for stable angina only), and family history of coronary artery
disease (OR=2.02, p=0.023; OR=2.17, p=0.047).
DISCUSSION
To the best of our knowledge, the association between
plasma adiponectin level and the cardiovascular risk
markers ox-LDL and total NO has not yet been evaluated
in stable and unstable angina patients. The findings of the
study demonstrate that plasma adiponectin levels are
closely associated with the inflammatory markers ox-LDL
and total NO in stable and unstable angina patients and that
these relationships persist after adjustment for conventional
cardiovascular risk factors. Also, this study revealed that
plasma adiponectin levels are lower in patients with stable
and unstable angina relative to control subjects, and this
disparity can be used to identify patients.
Decreased levels of circulating adiponectin have been
reported in patients with angiographically documented
coronary artery disease.
13,20 Our finding that adiponectin
was significantly lower in the stable and unstable angina
patients relative to the control subjects is in line with the
findings of Nakamura et al.
20 In another study conducted by
Stefan et al, no significant difference in adiponectin levels
was found between the stable and unstable angina
Figure 2 - Correlation between plasma adiponectin and ox-LDL
levels in control subjects (%), stable angina patients (#) and
unstable angina patients (D).
Figure 3 - Correlation between plasma adiponectin and total NO
levels in control subjects (%), stable angina patients (#) and
unstable angina patients (D).
Table 2 - Bivariate correlations between conventional
clinical risk factors and adiponectin levels.
Variable
Adiponectin
(mg/mL) p-value
Age (year) 0.016 0.85
Sex (women)* 0.310 0.01
BMI (kg/m
2) -0.289 0.01
Total cholesterol (mg/dL) -0.200 0.05
Triglycerides (mg/dL) -0.168 0.04
LDL-cholesterol (mg/dL) -0.259 0.01
HDL-cholesterol (mg/dL) 0.155 0.05
hsCRP (mg/L) -0.455 0.01
Hypertension* -0.337 0.01
Diabetes mellitus* -0.332 0.01
Family history of CAD* -0. 278 0.01
Smoking* -0.336 0.01
Statins* 0.236 0.04
*Point-biserial correlation. BMI, body mass index; LDL-cholesterol, low
density lipoprotein-cholesterol; HDL-cholesterol, high density lipoprotein-
cholesterol; hsCRP, high sensitivity C-reactive protein; CAD, coronary
artery disease.
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19 However, a recent study demonstrated that
plasma adiponectin levels in patients with acute coronary
syndrome are significantly lower than in those with stable
coronary artery disease and that low adiponectin levels are
correlated with the presence of complex coronary lesions.
17
Low adiponectin concentrations in unstable coronary artery
disease patients may contribute to coronary plaque vulner-
ability and thus may play a role in the pathophysiology of
acute coronary syndrome.
14 Therefore, coronary plaque
instability in the acute setting may account for the lower
adiponectin levels in our unstable angina patients relative to
the stable angina patients. Despite these findings, further
studies are required to address the difference in adiponectin
levels between stable and unstable angina patients.
Ox-LDL and NO play roles in all stages of coronary artery
disease.
24,25 Decreased adiponectin levels are an indicator
of increased oxidative state in the arterial wall and are
associated with high ox-LDL levels in patients with type 2
diabetes mellitus and coronary artery disease.
8 In our study,
plasma adiponectin was found to be inversely correlated
with ox-LDL. This correlation was strongest in the unstable
angina patients, weaker in the stable angina patients and
weakest in the control subjects, in accordance with the
above study. Ox-LDL is a key factor in plaque instability.
6
Given the protective effects of adiponectin against plaque
vulnerability, the mutual relationship between adiponectin
and ox-LDL may become lost during coronary artery
disease, especially in the unstable angina patients.
Endothelial dysfunction is a primary event in the
pathogenesis of coronary artery disease.
3 Adiponectin
directly promotes the production of NO by the endothe-
lium.
26 Hypoadiponectinemia is associated with endothelial
dysfunction in the peripheral arteries.
27 In our study,
adiponectin levels exhibited a positive correlation with the
total NO level. The correlation was weaker in the angina
patients than in the control subjects. A beneficial effect of
total NO elevation in patients with symptomatic coronary
artery disease has been reported.
28,29
Our finding of significantly lower total NO levels along
with elevated levels of the oxidative markers ox-LDL and
hsCRP in the angina patients demonstrates that adiponectin
may act through antioxidative and anti-inflammatory
mechanisms.
We found inverse associations between adiponectin levels
and other conventional cardiovascular risk markers that
were in accordance with the results of other studies.
30-33
In a multiple logistic regression analysis that adjusted
for other cardiovascular risk factors, a low plasma
adiponectin level was an independent negative predictor
of the presence of stable or unstable angina in the present
study, which is in accordance with the findings of Pilz
et al.
19 The correlation between adiponectin and the risk of
coronary heart disease is controversial. Although some
studies have reported an inverse relationship between
adiponectin level and the risk of coronary artery dis-
ease,
13,16,19,34 others failed to find a significant relation-
ship.
35,36 Differences in the underlying conditions of the
study populations may be the cause of the controversy.
Altogether, the negative correlations between adiponectin
and well-known cardiovascular risk factors in the above
literature and in our study highlight the anti-atherogenic
effects of elevated adiponectin levels. However, further
studies are required to determine the precise nature of this
relationship.
Hypoadiponectinemia is an early sign of a complex
cardiovascular risk factor leading to the development and
progression of atherosclerosis. However, the exact genomic
and environmental interactions contributing to hypoadipo-
nectinemia are not fully understood.
37 Single nucleotide
polymorphisms (SNPs) in the adiponectin gene have been
associated with the early onset of coronary artery disease
and low adiponectin levels.
37,38 Moreover, adipose tissue
dysfunction and visceral adiposity have been identified as
significant predictors of adiponectin levels.
39
There is no definite conclusion regarding the effects of
insulin onadiponectin production.
40 On the one hand, some in
vitro studies have indicated that insulin decreases adiponectin
production,
41 but in the clinical setting, long-term insulin
therapy has failed to increase adiponectin levels.
42 On the
other hand, in type B insulin resistance, high levels of insulin
are accompanied by high levels of adiponectin.
43
Table 3 - Multiple logistic regression analysis of independent predictors for stable and unstable angina.
Variable Stable angina Unstable angina
OR (95% CI) p-value OR (95% CI) p-value
Age (year) 1.26(1.35 – 1.63) 0.022 1.43(1.25 – 1.73) 0.042
Sex (men) 1.72(1.21 – 2.85) 0.071 1.32(1.17 – 2.64) 0.118
BMI (kg/m
2) 1.11(0.88 – 2.38) 0.140 1.21(1.12 – 2.28) 0.154
Total cholesterol (mg/dL) 1.28(1.02 – 3.55) 0.055 1.38(1.27 – 2.95) 0.075
Triglycerides (mg/dL) 1.48(1.24 – 2.33) 0.063 1.11(0.98 – 2.79) 0.053
LDL-cholesterol (mg/dL) 2.04(1.32 – 3.07) 0.056 1.92(1.83 – 3.01) 0.06
HDL-cholesterol (mg/dL) 0.52(0.47 – 1.29) 0.057 0.74(0.53 – 1.34) 0.071
hsCRP (mg/L) 1.62(1.57 – 3.26) 0.033 1.37(1.24 – 2.49) 0.003
Ox-LDL (ng/mL) 1.78(1.14 – 2.43) 0.014 2.01(1.74 – 2.27) 0.038
Total NO (mmol/L) 0.61(0.38 – 0.74) 0.008 0.76(0.62 – 0.98) 0.012
Adiponectin (mg/mL) 0.51(0.34 – 0.73) 0.023 0.59(0.44 – 0.81) 0.001
Hypertension 1.88(1.62 – 2.48) 0.069 2.11(1.97 – 2.53) 0.063
Diabetes mellitus 1.98(1.67 – 2.14) 0.054 2.47(2.28 – 2.84) 0.072
Family history of CAD 2.02(1.56 – 2.49) 0.023 2.17(1.53 – 2.79) 0.047
Smoking 1.31(1.18 – 2.59) 0.220 1.37(1.23 – 2.77) 0.09
Statins 0.65(0.58 – 0.82) 0.049 0.98(0.87 – 1.13) 0.106
Results are presented for b coefficient. OR, odds ratio; CI, confidence interval; CAD, coronary artery disease. BMI, body mass index; LDL-cholesterol, low
density lipoprotein-cholesterol; HDL-cholesterol, high density lipoprotein-cholesterol; hsCRP, high sensitivity C-reactive protein; NO, nitric oxide.
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1133Oxidative stress
44 and proinflammatory cytokines
45 sup-
press adiponectin expression, whereas a Mediterranean diet
and exercise increase plasma adiponectin levels.
46,47
In our study, body mass index (BMI) and diabetes
mellitus, two important cardiovascular risk factors, were
negatively associated with plasma adiponectin levels,
thereby indirectly corroborating the causal relationships
that may exist between adiposity, insulin resistance and
hypoadiponectinemia.
39,41 Other cardiovascular risk factors,
such as hypertension, smoking, family history of coronary
disease HDL-cholesterol, triglycerides, and cholesterol,
were also inversely associated with plasma adiponectin
level, whereas female sex and statin therapy were positively
associated with the plasma adiponectin level. According to
these findings and to the above literature, the conventional
cardiovascular risk factors may affect adiponectin levels,
and there may be mutual relationships between adiponectin
and the cardiovascular risk factors in the pathogenesis of
atherosclerosis.
One limitation of this study is the sample size. Although
our results follow a normal distribution, larger samples are
frequently used in clinical investigations.
CONCLUSIONS
The findings of this study indicate that plasma adipo-
nectin levels are lower in stable and unstable angina
patients than in control subjects. These lower adiponectin
levels may facilitate the stratification and identification of
stable and unstable angina patients. The correlations found
between adiponectin level and both NO and ox-LDL further
corroborate the antiatherogenic effects of adiponectin in
cardiovascular patients, and the in vivo mechanisms of
atherosclerotic progression that are elucidated by these
correlations may be useful for disease assessment.
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